Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 218.93 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.99 | |||||
Beneish M-Score | -1.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 1.1 | |||||
3-Year EPS without NRI Growth Rate | -1.7 | |||||
3-Year FCF Growth Rate | 5.2 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y Total Revenue Growth Rate | 66.9 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.25 | |||||
9-Day RSI | 57.72 | |||||
14-Day RSI | 53.15 | |||||
6-1 Month Momentum % | 60.26 | |||||
12-1 Month Momentum % | 113.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.58 | |||||
Quick Ratio | 5.43 | |||||
Cash Ratio | 5 | |||||
Days Inventory | 243.03 | |||||
Days Sales Outstanding | 54.29 | |||||
Days Payable | 276.64 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.99 | |||||
Operating Margin % | -238.1 | |||||
Net Margin % | -238.52 | |||||
FCF Margin % | -175.91 | |||||
ROE % | -89.34 | |||||
ROA % | -53.53 | |||||
ROIC % | -581.18 | |||||
ROC (Joel Greenblatt) % | -6167.53 | |||||
ROCE % | -57.15 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 30.43 | |||||
PB Ratio | 14.33 | |||||
Price-to-Tangible-Book | 14.96 | |||||
EV-to-EBIT | -13.24 | |||||
EV-to-EBITDA | -13.38 | |||||
EV-to-Revenue | 29.08 | |||||
EV-to-Forward-Revenue | 16.4 | |||||
EV-to-FCF | -16.53 | |||||
Price-to-Net-Current-Asset-Value | 16.8 | |||||
Price-to-Net-Cash | 21.57 | |||||
Earnings Yield (Greenblatt) % | -7.55 | |||||
FCF Yield % | -5.45 |